Cargando…
Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models
Mucinous peritoneal metastases (PM) generally respond poorly to systemic treatment, and there is a clear unmet need for new treatment strategies to improve survival and quality of life for patients with PM. In this work, the growth inhibitory effect of five drugs (oxaliplatin (OXA; 5 mg/kg), irinote...
Autores principales: | Fleten, Karianne Giller, Lund-Andersen, Christin, Waagene, Stein, Abrahamsen, Torveig Weum, Mørch, Yrr, Boye, Kjetil, Torgunrud, Annette, Flatmark, Kjersti |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243185/ https://www.ncbi.nlm.nih.gov/pubmed/32447231 http://dx.doi.org/10.1016/j.tranon.2020.100793 |
Ejemplares similares
-
Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer
por: Schee, Kristina, et al.
Publicado: (2012) -
Anti-Angiogenic Treatment in Pseudomyxoma Peritonei—Still a Strong Preclinical Rationale
por: Andersson, Yvonne, et al.
Publicado: (2021) -
Alginate Microsphere Encapsulation of Drug-Loaded Nanoparticles: A Novel Strategy for Intraperitoneal Drug Delivery
por: Fleten, Karianne Giller, et al.
Publicado: (2022) -
Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei
por: Flatmark, Kjersti, et al.
Publicado: (2021) -
A comprehensive framework for analysis of microRNA sequencing data in metastatic colorectal cancer
por: Høye, Eirik, et al.
Publicado: (2022)